Articles tagged "B cells"

2018 American Transplant Congress
B Cell Immune Repertoire Sequencing Identifies Pre-Transplant Rejection Risk
S. Pineda,^1,2 T. Sigdel,¹ J. Liberto,¹ K. Roskin,³ S. Robin,³ M. Sirota,² M. Sarwal.¹
¹Surgery, UCSF, SF; ²ICHS, UCSF, SF; ³Pathology, Stanford, Stanford.
Background: The diversity of the B cell immune repertoire may drive humoral injury and rejection in organ transplantation (tx).Methods: We utilized advances in next-generation sequencing…
2018 American Transplant Congress
The Impact of Childhood Solid Organ Transplantation on B-Cell Maturation
L. Ionescu,¹ T. Blydt-Hansen,² B. Foster,⁷ S. Mital,³ L. Hamiwka,⁵ U. Allan,³ V. Phan,⁴ P. Birk,⁶ C. Morgan,¹ S. Urschel.¹
¹U of Alberta, Edmonton, Canada; ²U of BC, Vancouver, Canada; ³Hospital for Sick Children, Toronto, Canada; ⁴U de Montreal, Montreal, Canada; ⁵U of Calgary, Calgary, Canada; ⁶U of Manitoba, Winnipeg, Canada; ⁷McGill University, Montreal, Canada.
Background:The developing immune system of childhood promotes better graft acceptance and longevity but also higher risk for infections and post-transplant (Tx) lymphoproliferative disorders. This may…
2018 American Transplant Congress
TLR-Activated Bregs Promote Islet Allograft Tolerance in an IL-10-Independent and TGF-β-Dependent Manner
L. Kojima, K. Lee, K. Deng, H. Tector, C. Dai, S. Kimura, C. Rickert, H. Yeh, J. Markmann.
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.
Background: We previously demonstrated the potent capacity of regulatory B cells (Bregs) to mitigate allograft immunity. Recently, we produced TLR-activated B cells in vitro that…
2018 American Transplant Congress
Ex Vivo Expanded Regulatory B Cells Promote Allograft Survival through IL-10-Dependent Pathway
K. Lee, K. Deng, L. Kojima, C. Dai, C. Rickert, H. Yeh, J. Markmann.
Massachusetts General Hospital, Boston.
Immunomodulatory capacity of B cells make them a promising therapeutic tool for autoimmune and alloimmune response in patients. We found that transplant tolerance induced by…
2018 American Transplant Congress
CD19+ Cell Ratio as a Predictive Marker of Antibody Mediated Rejection in ABO Incompatible Kidney Transplantation
K. Unagami,¹ R. Maenosono,² M. Furusawa,² Y. Kakuta,² M. Okumi,² H. Ishida,² K. Tanabe,² K. Nitta.¹
¹Nephrology, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan.
Background: Rituximab has been suggested to deplete B cells and decrease the possibility of antibody mediated rejection (AMR) in ABO-incompatible living kidney transplantation (ABO-ILKT). We…
2018 American Transplant Congress
Targeting Plasma Cells with Anti-CD38mAb (Daratumumab) and CXCR4 Antagonist (Plerixafor) for Desensitization
J. Kwun,¹ E. Brian,¹ M. Manook,¹ J. Park,¹ K. Freischlag,¹ J. Yoon,¹ J. Yi,¹ M. Stegall,² S. Knechtle.¹
¹Surgery, Duke University, Durham, NC; ²Surgery, Mayo Clinic, Rochester, MN.
[Introduction] Sensitized patients comprise a significant portion (30%) of candidates on the transplant waiting list. Unfortunately for sensitized patients, the presence of donor-specific antibodies (DSA)…
2018 American Transplant Congress
The Incidence of Polyomavirus-BK and Cytomegalovirus Infections in Renal Transplant Recipients Following Rituximab Administration
A. Kraljevic, C. D'Agostino, C. Kane, K. Cunningham, A. Shetty, C. Richardson.
Northwestern Memorial Hospital, Chicago, IL.
Rituximab is an antibody that binds to the CD20 antigen on B cells resulting in rapid and prolonged depletion. At Northwestern Memorial Hospital, a single…
2018 American Transplant Congress
Impact of De Novo DSA (DnDSA) on Outcomes in HLA-Sensitized (HS) Patients Transplanted after IVIG + Rituximab Desensitization (DES)
A. Vo,¹ O. Aubert,² H. Edmund,¹ A. Peng,¹ R. Najjar,¹ S. Supreet,¹ J. Choi,¹ K. Lim,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²Paris Translational Research Center for Organ Transplantation, Necker Hospital, Paris, France.
Introduction: Highly-HLA sensitized patients (HS) with donor specific antibodies (DSA) at transplant are at risk for Type 1 ABMR. However, the incidence of Type 2…
2018 American Transplant Congress
TACI Polymorphisms Associated with Allograft Rejection in Mice and in Man
M. Barbosa,¹ E. Farkash,² J. Platt,³ M. Cascalho.³
¹Surgery, University of Michigan, Ann Arbor, MI; ²Pathology, University of Michigan, Ann Arbor, MI; ³Surgery/Microbiology and Immunology, University of Michigan, Ann Arbor, MI.
Trans-membrane Activator and CAML Interactor (TACI) controls B cell differentiation and memory and exists as numerous allelic variants in healthy individuals. In fact, TACI is…
2018 American Transplant Congress
Prolonged Cold Ischemia Storage of Renal Allografts Shifts DSA Specificity and Enchances Glomerular Injury
V. Gorbacheva, R. Fan, W. Baldwin, A. Valujskikh.
Immunology, Cleveland Clinic, Cleveland, OH.
Prolonged cold ischemia storage (CIS) of donor organs is a major risk factor for acute and chronic graft injury. The goal of this study was…